ICAR's biotech push earns activists' wrath

Image
Sanjeeb Mukherjee New Delhi
Last Updated : Jan 21 2013 | 2:31 AM IST

The Union government is putting in renewed efforts on agri-biotech research through the Indian Council of Agricultural Research (ICAR), which has been active in this field for the past several years. The initiatives, however, are not going down well with the civil society, even as those are drawing a positive initial response from the private sector.

The emphasis is multi-pronged — and is focused on the need to develop the next generation of crop biotechnology using the latest methods and findings.

Officials says the focus in the upcoming budget will be on enhanced allocation to agriculture research and technology, by setting up two dedicated institutes for undertaking research on transgenic and bio-technology crops, besides a Rs 150-200 crore pan-India programme to develop an Indian version of biotech cotton which can be patented.

The first in the endeavours, called the Indian Institute of Agri Biotech Management, will be set up in Ranchi with a capital investment of around Rs 287 crore. The second, called the National Institute of Biotech Stress Management, will exclusively undertake research on transgenic and bio-technology crops. It will be set up in Chhattisgarh with an investment of Rs 121 crore.

The government’s expenditure and finance committee has okayed the setting up these two institutes.

Both of them will be deemed universities,” according to a senior crop scientist of ICAR.

“They will work exclusively to undertake the next generation research on indigenous biotech crops, transgenic, nano technology in crops, animal husbandry and fisheries,” he told Business Standard.

For the latest endeavour, authorities have solicited the help of the private sector, which has been an equal player in crop research since the last several years.

All the same, the new focus has not pleased the civil society and opponents of biotech crops. They want the government to develop proper protocol to take people on board on these moves.

The private sector, on its part, has shown initial interests in partnering with the government. There are already many collaborations between the two in the field of biotech research, but the sector feels that the fresh impetus will give it more opportunity.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 13 2012 | 1:34 AM IST

Next Story